Hims & Hers Health, Inc. $HIMS Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC trimmed its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 51.0% during the third quarter, Holdings Channel reports. The firm owned 30,430 shares of the company’s stock after selling 31,617 shares during the period. Oak Ridge Investments LLC’s holdings in Hims & Hers Health were worth $1,726,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HIMS. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter worth $28,000. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health during the second quarter valued at $26,000. Quaker Wealth Management LLC bought a new position in shares of Hims & Hers Health during the second quarter worth about $29,000. Bessemer Group Inc. increased its holdings in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. Finally, Hilltop National Bank bought a new stake in Hims & Hers Health in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $31.38 on Friday. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The stock has a fifty day moving average price of $35.79 and a two-hundred day moving average price of $45.68. The firm has a market cap of $7.14 billion, a P/E ratio of 58.11, a PEG ratio of 5.32 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the company earned $0.32 EPS. The company’s quarterly revenue was up 49.2% compared to the same quarter last year. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has initiated a share buyback plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Leerink Partnrs raised Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Evercore ISI assumed coverage on Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 target price on the stock. Barclays started coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target for the company. Finally, Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $44.54.

Insider Activity at Hims & Hers Health

In other news, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 9,070 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.79, for a total value of $306,475.30. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at $3,095,738.43. This trade represents a 9.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 125,544 shares of company stock worth $4,620,821. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.